FDA
-
-
-
-
-
-
-
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
-
-
-
-
-
-
-
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
-
-
-
-
-
-
-
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
-
-
-
-
-
-
-
Pre-Open 11/20: (ARAV) (I) (TGT) Higher (PDD) (URBN) (MUX) Lower (more...)
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Announces FDA Acceptance of IND for CTLA-4 Probody Therapeutic
-
-
-
-
-
322,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

